Replies to post #32516 on Marker Therapeutics Inc (MRKR)

[Phantom Lord]

Until we see the trial design there is no way to know what they are planning. The BCM study was done in combination w/ chemotherapy. HERE is the poster presented at AACR and HERE is the PowerPoint from the investor presentation they gave.

Why not MT-601 as a stand alone treatment?

Its possible they have two arms of the trial, although that is more likely a design for a PII. More likely for this PI is they wanted to keep the trial design as similar to the BCM study as possible with the exception of the manufacturing improvements. Again, we'll know more when we see an actual trial design.

Will the side affects of chemotherapy now going to tacked on as side affects of MT-601?

No. The side effects of chemo are pretty well known. They will be able to differentiate those from any side effects of the MultiTAA of which we already know are very few.